Turkish Courts Invalidate Bad Faith 'Clindoxyl' Trademark Registration in Favor of GSK

A Turkish court has ruled in favor of GlaxoSmithKline Plc (GSK) in a high-profile trademark dispute, invalidating a third party's registration of the 'Clindoxyl' mark on grounds of bad faith. The decision, which was subsequently upheld by both the Regional Court and the Court of Cassation, underscores the Turkish judiciary's commitment to protecting genuine trademark rights against opportunistic registrations.

The dispute centered on the 'Clindoxyl' trademark, which had been used commercially by GSK in Türkiye since 2010, particularly for acne treatment products. GSK, through its affiliate Stiefel Laboratoires, Inc., originally applied for and registered the mark in Class 5 in 2007. However, the registration lapsed in 2016 due to an unintentional failure to renew.

In 2019, a third party obtained registration for the 'Clindoxyl' trademark in Class 5. Shortly after securing the registration, the defendant issued a cease-and-desist letter to GSK Türkiye, alleging trademark infringement and threatening to seek removal of GSK's products from the market based on the new registration.

GSK responded promptly, asserting its status as the genuine rights holder and demanding assignment of the trademark. The defendant, however, requested a substantial payment in exchange for the assignment, which GSK viewed as evidence of bad faith.

GSK initiated an invalidation action, arguing that the defendant had deliberately exploited the lapse in registration to benefit from GSK's established brand reputation and commercial presence. The defendant countered by denying bad faith, claiming that GSK lacked a valid registration and that the intended use of the mark pertained to different goods—specifically, room fragrances in Class 5, as opposed to GSK's use for goods in Class 3.

The Izmir Intellectual Property Court found in favor of GSK, ruling that the defendant's registration was invalid. The court determined that GSK was the genuine rights holder, having used the 'Clindoxyl' mark both in Türkiye and internationally well before the defendant's application. The court concluded that the defendant's registration was not coincidental and was intended to secure an unfair advantage despite knowledge of GSK's prior rights (Izmir IP Court, Merit No. 2020/80, Decision No. 2021/95, dated 16.06.2021).

The defendant appealed the decision, but the Izmir Regional Court rejected the appeal (Merit No. 2021/1077, Decision No. 2024/421, dated 13.03.2024). A further appeal to the Court of Cassation was also unsuccessful, with the 11th Civil Chamber upholding the invalidation (Merit No. 2024/3134, Decision No. 2025/1450, dated 04.03.2025).

Following the final court decision, the Turkish Patent and Trademark Office declared the defendant's trademark registration entirely invalid with retroactive effect, clearing the way for GSK to re-register its own mark.

This outcome not only removes the basis for potential infringement claims against GSK but also eliminates an obstacle to its own trademark registration. The ruling is seen as a strong precedent for protecting trademark holders in Türkiye from bad faith registrations, particularly in cases where lapses in registration are exploited by third parties.

The courts emphasized that trademark rights are not solely determined by registry entries but also by actual use, commercial recognition, and ethical conduct in trade. By referencing earlier jurisprudence and highlighting the responsibilities of diligent traders, the judiciary distinguished between opportunistic filings and legitimate registrations.

The decision is expected to contribute to the development of trademark law in Türkiye, providing a robust legal tool to prevent misuse of the registration system through bad faith actions.